Latest update · Jun 7, 2026
Verdict: The Direction Is Right. The Details Are Dangerously Incomplete.
The Case for Hims & Hers Health: Why the Market is Wrong About the GLP-1 Shakeout
Hims & Hers is an incredibly resilient, cash-rich digital health leader that the market has fundamentally mispriced at under 2.0x forward revenues due to a short-sighted overreaction to temporary GLP-1 compounding regulations.
Turning Regulatory Turbulence into an Asymmetric Buying Opportunity: The Case for Hims & Hers Health The world of growth investing rarely offers second chances. When a hyper-growth company experiences a sharp 60% drawdown from its market highs, the investing community often reacts with panic rather than analytical curiosity. This is exactly what is happening with Hims &…